ALOX15 and Alzheimer disease: Since circulating LXA5 levels were suppressed in patients with ACLF, in whom EPA levels were not different from those of patients with AD and healthy subjects, this observation likely reflects reduced 15-LOX rather than limited access to its biosynthetic substrate (i.e., EPA).